No trading action warranted. This is a purely administrative AIM Rule 17 disclosure with zero financial or operational impact on HUTCHMED. Monitor for any future filings that might indicate a broader governance concern, but none is present here.
Price Chart
Executive Summary
HUTCHMED filed a routine 6-K disclosing that its Chairman, Dr. Dan Eldar, was formerly a director of S.D. Sight Diagnostics Ltd., which entered insolvency proceedings in Israel. The filing explicitly states the insolvency does not involve HUTCHMED or its operations, and the amount involved (~$1M) is immaterial relative to HUTCHMED's $2.1B market cap. This is a purely administrative AIM Rule disclosure with no financial or operational impact on the company.
Key Facts
- Chairman Dr. Dan Eldar was a director of S.D. Sight Diagnostics from Dec 2018 to Mar 2026.
- S.D. Sight entered insolvency proceedings in Israel; a trustee was appointed on May 28, 2026.
- The amount involved is approximately NIS 3,057,876 (~US$1,019,292).
- Neither S.D. Sight nor Hutchison Water Israel E.P.C Ltd (which holds ~9.98% of S.D. Sight) is part of HUTCHMED.
- The Board states the proceedings have no impact on HUTCHMED's businesses or operations.
Financial Impact
Immaterial — ~$1M insolvency proceeding involving an unrelated third party, less than 0.05% of HUTCHMED's market cap.
Risk Factors
- Reputational risk from association of a director with an insolvent entity, though the company has explicitly disclaimed any operational link.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001648257-26-000051 |
| Document: hcm-20260818xex99d1.htm | 0001648257-26-000051 |
| Document: 0001648257-26-000051-index-headers.html | 0001648257-26-000051 |
| Document: 0001648257-26-000051-index.html | 0001648257-26-000051 |
| Document: 0001648257-26-000051.txt | 0001648257-26-000051 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 3, 2026 29d ago | 6-K | $14.11 $12.82 | ▼ −9.14% | ▼ −7.99% | $14.31 (+1.42%) |
Aug 31, 2026 4w ago | 6-K | $12.12 $13.88 | ▲ +14.52% | ▲ +14.66% | $14.31 (+18.07%) |
Aug 18, 2026 6w ago | 6-K | $12.64 $12.26 | ▼ −3.01% | ▼ −2.81% | $14.31 (+13.21%) |
Aug 17, 2026 6w ago | 6-K | $12.56 $12.18 | ▼ −3.03% | ▼ −1.83% | $14.31 (+13.93%) |
Aug 17, 2026 6w ago | Press Release | $12.56 $12.18 | ▼ −3.03% | ▼ −1.83% | $14.31 (+13.93%) |
Jul 30, 2026 9w ago | 6-K | $10.77 $11.83 | ▲ +9.84% | ▲ +6.22% | $14.31 (+32.87%) |
Jul 2, 2026 13w ago | 6-K | $11.44 $10.98 | ▼ −4.02% | ▼ −4.95% | $14.31 (+25.09%) |
Jun 30, 2026 13w ago | 6-K | $10.76 $11.65 | ▲ +8.27% | ▲ +7.67% | $14.31 (+32.99%) |
Jun 30, 2026 13w ago | Press Release | $10.76 $11.65 | ▲ +8.27% | ▲ +7.67% | $14.31 (+32.99%) |
Jun 29, 2026 13w ago | 6-K | $10.71 $11.65 | ▲ +8.78% | ▲ +7.39% | $14.31 (+33.61%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access